Head of Data Science
As the head of Calico’s Data Science efforts, Matt leads his team in using advanced computational methods together with high-dimensional datasets to better understand the interconnected mechanisms that drive aging-related diseases, with the ultimate goal of translating these findings into new therapies.
Matt has over 15 years of experience applying computational approaches to fundamental questions in drug discovery and development. Prior to joining Calico, he led the precision medicine efforts at Seattle Genetics, where he was head of the bioinformatics, companion diagnostics, and translational biomarker groups. During this time, Matt and his team provided the scientific and clinical biomarker results that supported the approvals of PADCEV in locally advanced or metastatic bladder cancer, Tukysa in second-line HER2+ breast cancer, and the expansion of ADCETRIS into CD30 expressing peripheral T-cell lymphoma and subcutaneous T-cell lymphoma. He has an extensive background in applying computational biology to drug development and has held leadership roles at AstraZeneca, Merrimack Pharmaceuticals, and Silver Creek Therapeutics.
Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis
HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B
Single-Cell Quantitative HER2 Measurement Identifies Heterogeneity and Distinct Subgroups within Traditionally Defined HER2-Positive Patients